Inhibitors of leukotriene A4 hydrolase

1. A compound having the Formula (I):

wherein:

R is the group;

r is 0;

q is 1;

R 1a , R 1b , R 1c , R 1d and R 1e are each independently hydrogen, OR 10 , C(O)OR 10 , C(O)R 10 , optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 3 -C 15 cycloalkyl, optionally substituted C 3 -C 15 cycloalkenyl, halo, cyano, optionally substituted aryl, optionally substituted 3- to 18-membered heteroaryl, or optionally substituted 3- to 18-membered heterocyclyl;

R 3 is —O—;

R 4 is a direct bond;

each R 5a and R 6a are each independently hydrogen and optionally substituted C 1 -C 6 alkyl;

R 7 is —C(R 5b ) 2 —R 15 ;

each R 5b is independently selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl:

R 15 is selected from the group consisting of C(O)R 10 , C(O)OR 10 , C(O)—R 13 —N(R 10 )R 11 , optionally substituted aryl, and optionally substituted 3- to 18-membered heteroaryl;

each R 9 is independently —OR 10 , optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, halo, optionally substituted aryl, or optionally substituted heteroaryl;

each R 10 and R 11 is independently selected from the group consisting of hydrogen, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 3 -C 15 cycloalkyl, optionally substituted C 3 -C 15 cycloalkenyl, optionally substituted aryl, optionally substituted 3- to 18-membered heteroaryl, and optionally substituted 3- to 18-membered heterocyclyl;

each R 13 is independently a direct bond, an optionally substituted straight or branched C 1 to C 12 alkylene chain, an optionally substituted straight or branched C 2 to C 12 alkenylene chain, or an optionally substituted straight or branched C 3 to C 12 alkynylene chain; and

R 14 is an optionally substituted pyrrolidinyl;

wherein each of the optionally substituted moieties is independently optionally substituted by one, two or three substituents independently selected from the group consisting of —C 1 -C 12 alkyl, —C 2 -C 12 alkenyl, —C 2 -C 12 alkynyl, —C 3 -C 15 cycloalkyl, —C 3 -C 15 cycloalkenyl, C 3 -C 15 cycloalkynyl, -3 to 18-membered heterocyclic, —F, —Cl, —Br, —I, —OH, —NO 2 , —N 3 , —CN, —NH 2 , oxo, thioxo, —NHR x , —NR x R x , dialkylamino, -diarylamino, -diheteroarylamino, —OR x , —C(O)OR y , —C(O)R y , —C(O)C(O)R y , —OCO 2 R y , —OC(O)R y , OC(O)C(O)R y , —NHC(O)R y , —NHCO 2 R y , —NHC(O)C(O)R y , —NHC(S)NH 2 , —NHC(S)NHR x , —NHC(NH)NH 2 , —NHC(NH)NHR x , —NHC(NH)R x , —C(NH)NHR x , —NR x C(O)R x , —NR x CO 2 R y , —NR x C(O)C(O)R y , —NR x C(S)NH 2 , —NR x C(O)NR x R x , —NR x S(O) 2 NR x R x , —NR x C(S)NHR x , —NR x C(NH)NH 2 , —NR x C(NH)NHR x , —NR x C(NH)R x , —C(NR x )NHR x —S(O) n R y , —NHSO 2 R x , —CH 2 NH 2 , —CH 2 SO 2 CH 3 , —(C═NR x )R x ; -aryl, -arylalkyl, -3 to 18-membered heteroaryl, -3 to 18-membered heteroarylalkyl, polyalkoxyalkyl, -polyalkoxy, -methoxymethoxy, -methoxyethoxy, —SH, —S—R x , and -methylthiomethyl,

R x is selected from the group consisting of hydrogen, —C 1 -C 12 alkyl, —C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, —C 3 -C 15 cycloalkyl, -aryl, -3 to 18-membered heteroaryl, and -3 to 18-membered heterocyclic;

—R y is selected from the group consisting of hydrogen, —C 1 -C 12 alkyl, —C 2 -C 12 alkenyl, —C 2 -C 12 alkynyl, —C 3 -C 15 cycloalkyl, -aryl, -3 to 18-membered heteroaryl, -3 to 18-membered heterocyclic, —NH 2 , —NH—C1-C12 alkyl, —NH—C 2 -C 12 alkenyl, —NH—C 2 -C 12 -alkynyl, —NH—C 3 -C 15 cycloalkyl, —NH-aryl, —NH-3 to 18-membered heteroaryl, and —NH-3 to 18-membered heterocyclic, and

n is 0, 1 or 2:

as a single stereoisomer or as a mixture of stereoisomers; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 15 is C(O)OR 10 or optionally substituted phenyl.

3. The compound of claim 1 , wherein R 14 is optionally substituted pyrolidin-2-yl or optionally substituted pyrolidin-3-yl.

4. The compound of claim 3 , wherein R 14 is selected from:

wherein R 16 is selected from the group consisting of hydrogen, and optionally substituted C 1 -C 12 alkyl, C(O)R 10 , C(O)—R 13 —N(R 10 )R 11 , and C(O)OR 10 .

5. The compound of claim 4 , wherein R 16 is optionally substituted benzyl.

6. The compound of claim 1 , wherein R 1a is hydrogen, C(O)OR 10 , C(O)R 10 , C(O)—R 13 —N(R 10 )R 11 , optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 3 -C 15 cycloalkyl, optionally substituted C 3 -C 15 cycloalkenyl, halo, cyano, optionally substituted aryl, optionally substituted 3- to 18-membered heteroaryl, and optionally substituted 3- to 18-membered heterocyclyl.

7. A compound selected from the compounds shown in the following Table or a pharmaceutically acceptable salt thereof:

X

Y

8. The compound of claim 1 , wherein each R 5b is hydrogen.

9. The compound of claim 2 , wherein R 15 is unsubstituted phenyl or phenyl substituted with a substituent selected from the group consisting of C(O)OR10′ and halo, wherein R 10 ′ is hydrogen or C 1 -C 6 alkyl.

10. The compound of claim 9 , wherein R 15 is phenyl substituted with C(O)OH or C(O)OCH 3 .

11. The compound of claim 9 , wherein R 15 is phenyl substituted with halo.

12. The compound of claim 4 , wherein R 16 is selected from the group consisting of hydrogen, optionally substituted C 1 -C 12 alkyl, and C(O)OR 10 .

13. The compound of claim 5 , wherein the optionally substituted benzyl is a benzyl optionally substituted with C(O)OH, C(O)OCH 3 , and halo.

14. The compound of claim 6 , wherein R 1a is hydrogen, C(O)OR 10 , C(O)R 10 , C(O)—R 13 —N(R 10 )R 11 , optionally substituted alkyl, halo, optionally substituted phenyl, furanyl, thienyl, thiazolyl, or optionally substituted oxazolyl; and wherein R 1b , R 1c , R 1d and R 1e are each hydrogen.

15. The compound of claim 14 , wherein R 1a is halo.

16. The compound of claim 14 , wherein R 1a is oxazolyl or thiazolyl.

17. The compound of claim 7 , wherein the compound is:

18. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

19. A method of treating an inflammatory disease or autoimmune disorder, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the inflammatory or autoimmune disorder is selected from the group consisting of a pulmonary or respiratory tract inflammation and an inflammatory skin condition.

20. The method of claim 19 , wherein the inflammatory disease or autoimmune disorder is a pulmonary or respiratory tract inflammation.

21. The method of claim 19 , wherein the mammal is a human.

22. The method of claim 20 , wherein the pulmonary or respiratory tract inflammation is selected from the group consisting of asthma, chronic bronchitis, bronchiolitis, bronchiolitis obliterans, allergic inflammation of the respiratory tract, eosinophilic granuloma, pneumonias, pulmonary fibroses, pulmonary manifestations of connective tissue diseases, acute or chronic lung injury, chronic obstructive pulmonary diseases, adult respiratory distress syndrome, and other non-infectious inflammatory disorders of the lung characterized by eosinophil infiltration.

23. The method of claim 19 , wherein the disease or disorder is cystic fibrosis.

24. The method of claim 19 , wherein the disease or disorder is an inflammatory skin condition.